Absolute Markets Insights has announced the addition of new informative data titled as, Dengue Drugs Market to its extensive repository. The aim of this report is to enable the readers to focus on some significant aspects of the businesses such as, recent developments, technological platforms, various standard operating procedures, and tools, which helps to boost the performance of the industries. Primary and secondary research techniques have been used to examine the desired data effectively.

Different financial facts and figures have been elaborated by using effective graphical presentation techniques such as, graphs, charts, diagrams and tables which helps to understand the complex things clearly to the readers. Additionally, it offers various internal and external attributes which are driving or restraining the flow of the businesses. This comprehensive analysis ponders the approaches to discover the global opportunities to get customers rapidly, which helps to develop the businesses.

Global Dengue Drugs Market is expected to grow at a CAGR of +2.6% from 2021 to 2030

Click to view the full report: https://www.absolutemarketsinsights.com/reports/Dengue-Drugs-Market-617

Top Key Players includes: AbbVie Inc., ABIVAX, GSK group of companies, Johnson & Johnson Services, Inc., Micro Labs Ltd., Pfizer Inc., Sanofi, Sun Pharma and Takeda Pharmaceutical Company Limited

The reported cases of dengue to World Health Organization in 2019 were 4.2 million and are spreading to multiple countries. This high number of patients has triggered numerous research and development activities for developing effective and economical dengue drugs. For instance, Indian Ministry of Science and Technology in partnership with Sun Pharmaceutical Industries Ltd. developed an herbal medicine for dengue in 2019. Similarly, 60 Degrees Pharmaceuticals of Singapore was granted a patent for a novel dengue drug named Celgosivir in 2014. These on-going developments of newer drugs are anticipated to drive the global dengue drugs market in forecast years. The maximum potential market for dengue drugs is US $338 million per year. Over 2-3 billion of the world’s population is at risk of contracting dengue. Approximately 3–6% of clinical cases progress from an acute but uncomplicated febrile form of the disease to dengue hemorrhagic fever or dengue shock syndrome. This manifestation is reported to be fatal in nature. Drugs are a intervention that may be useful for patients who contract dengue because they did not receive an approved dengue vaccine or for whom prior vaccination was ineffective.

Global Dengue Drugs Market: Report Scope

By Distribution Channel

  • Hospitals
  • Clinics
  • Pharmacies
  • Others

By Type

  • Rx
  • OTC

By Drug Class

  • Acetaminophen
  • Rehydration therapy
  • Others

By Route of Administration

  • Oral
  • Intravenous

By Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America

Key Benefits for Industry Participants & Stakeholders:

  • Industry drivers, restraints, and opportunities covered in the study
  • Neutral viewpoint on the market performance
  • Recent industry trends and developments
  • Competitive landscape & approaches of major players
  • Potential & niche segments and regions exhibiting promising growth covered
  • Historical, current, and projected market size, in terms of value
  • Detailed analysis of the Dengue Drugs Market

Contact Us:

Company: Absolute Markets Insights

Email Id: [email protected]

Phone: IN +91-740-024-2424, US +1-510-420-1213

Contact Name: Shreyas Tanna

Website: www.absolutemarketsinsights.com/